Key Points
- CEO August Troendle sold 668 shares on Dec. 3 at an average price of $590.69 for $394,580.92, reducing his stake by 0.10% while still owning 646,184 shares (≈$381.7M).
- Medpace beat Q3 estimates and set FY2025 guidance of 14.600–14.860 EPS; the stock traded near $542 (market cap $15.27B, P/E 37.9) and carries an average analyst rating of "Hold" with a $487.18 average price target.
Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) CEO August Troendle sold 668 shares of Medpace stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $590.69, for a total value of $394,580.92. Following the sale, the chief executive officer directly owned 646,184 shares of the company's stock, valued at approximately $381,694,426.96. This trade represents a 0.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Medpace Trading Down 0.5%
Shares of Medpace stock traded down $2.78 during trading on Friday, hitting $542.00. 16,384 shares of the stock traded hands, compared to its average volume of 408,522. The stock's fifty day simple moving average is $566.87 and its 200 day simple moving average is $451.00. The firm has a market cap of $15.27 billion, a P/E ratio of 37.90, a price-to-earnings-growth ratio of 2.17 and a beta of 1.43. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $626.26.
Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, beating analysts' consensus estimates of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The business had revenue of $659.90 million for the quarter, compared to the consensus estimate of $640.49 million. During the same quarter last year, the firm posted $3.01 EPS. The company's revenue for the quarter was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, equities analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.
Institutional Investors Weigh In On Medpace
A number of large investors have recently modified their holdings of MEDP. Quent Capital LLC acquired a new stake in shares of Medpace in the 3rd quarter valued at approximately $25,000. Optiver Holding B.V. bought a new position in Medpace during the third quarter worth about $27,000. Quarry LP bought a new position in Medpace during the third quarter worth about $35,000. Root Financial Partners LLC acquired a new position in Medpace during the third quarter worth approximately $38,000. Finally, Geneos Wealth Management Inc. lifted its position in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock worth $29,000 after acquiring an additional 37 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.
Analysts Set New Price Targets
Several analysts have issued reports on the company. Zacks Research raised Medpace from a "hold" rating to a "strong-buy" rating in a research report on Monday, October 27th. Robert W. Baird set a $613.00 price objective on Medpace in a research report on Friday, October 24th. Wall Street Zen upgraded Medpace from a "hold" rating to a "buy" rating in a research note on Saturday, October 25th. Truist Financial set a $555.00 price target on shares of Medpace in a research report on Monday, October 27th. Finally, Weiss Ratings restated a "buy (b)" rating on shares of Medpace in a report on Friday, October 31st. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, ten have issued a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $487.18.
View Our Latest Stock Report on Medpace
About Medpace
(
Get Free Report)
Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
